India’s healthcare industry is rapidly advancing, with a strong focus on manufacturing affordable medical devices to address the needs of a growing population. The industry is projected to grow at a CAGR of 15-17%, driven by innovation, government initiatives like “Make in India,” and increasing investments in medical technology.
A significant area of concern is urological issues, with nearly 200 million Indians expected to suffer from kidney and urinary tract-related ailments by 2030. Rising cases of diabetes and hypertension further exacerbate these conditions, creating demand for cost-effective diagnostic and treatment devices. India’s ability to produce inexpensive, high-quality urological devices positions it as a key player in the global market, offering immense scope for growth and addressing critical health challenges.
Share Price
The shares of Tejnaksh Healthcare are trading at Rs. 25 up by 6.38% from its previous close of Rs. 23.5 as of December 16, 2024. The shares also touched a high of Rs. 26 during the intraday trade.
Addressing Urinary Issues in Aging Populations
With a growing elderly population, urinary infections and uncontrolled urine flow have become prevalent health concerns. Recognizing this, Pflow has developed an innovative, disposable, and portable urine flow measurement test. This home-based solution empowers individuals to detect potential urinary issues early, enabling timely medical intervention and improving quality of life.
Recent Update
Pflow Secures Prestigious Indian Patent
We are delighted to announce that Pflow, an innovative product designed by Dr. Ashish Rawandale Patil, Managing Director of our company, has been granted an Indian patent. This landmark achievement makes Dr. Patil the only urologist in India to hold 11 patents to date. Pflow is a revolutionary, disposable, and portable home-based urine flow measurement test that enables individuals to detect potential urinary issues early from the comfort of their homes. This innovation is poised to transform early diagnosis and improve healthcare outcomes for urinary and kidney-related conditions in India.
National Recognition on Shark Tank India
Pflow gained national recognition with its feature on Shark Tank India Season 2, Episode 15, where its revolutionary potential was widely appreciated. The platform highlighted Pflow’s ability to address widespread health challenges, significantly enhancing its visibility and credibility. By showcasing its innovative approach, Shark Tank underscored Pflow’s role in transforming kidney healthcare and empowering individuals with an accessible diagnostic tool.
Celebrating a Milestone Achievement
This patent represents a significant milestone in the journey of Pflow and reaffirms our commitment to healthcare innovation. Dr. Patil expressed his gratitude, stating, “This achievement reflects years of dedication to addressing critical healthcare needs and making diagnostics more accessible.”
About the Company
Incorporated in 2008, Tejnaksh Healthcare Ltd (THL) is a leading provider of healthcare services and pharmacies, primarily operating in Mumbai and other regions of Maharashtra. The company specializes in urology and dentistry, managing 13 urology clinics, 4 urology hospitals, and 2 dental super-specialty clinics, offering advanced and specialized care. Additionally, THL operates a teaching institute recognized by the Ministry of Health and Family Welfare, contributing to medical education and skill development. With a strong focus on quality healthcare, THL continues to expand its presence and deliver accessible, state-of-the-art medical services to communities across Maharashtra.
Written By: Dipangshu Kundu
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
